Background and Purpose-Endovascular thrombectomy (EVT) is effective for acute ischemic stroke with large vessel occlusion and National Institutes of Health Stroke Scale (NIHSS) ≥6. However, EVT benefit for mild deficits large vessel occlusions (NIHSS, <6) is uncertain. We evaluated EVT efficacy and safety in mild strokes with large vessel occlusion. Methods-A retrospective cohort of patients with anterior circulation large vessel occlusion and NIHSS <6 presenting within 24 hours from last seen normal were pooled. Patients were divided into 2 groups: EVT or medical management. Ninety-day mRS of 0 to 1 was the primary outcome, mRS of 0 to 2 was the secondary. Symptomatic intracerebral hemorrhage was the safety outcome. Clinical outcomes were compared through a multivariable logistic regression after adjusting for age, presentation NIHSS, time last seen normal to presentation, center, IV alteplase, Alberta Stroke Program early computed tomographic score, and thrombus location. We then performed propensity score matching as a sensitivity analysis. Results were also stratified by thrombus location. Results-Two hundred fourteen patients (EVT, 124; medical management, 90) were included from 8 US and Spain centers between January 2012 and March 2017. The groups were similar in age, Alberta Stroke Program early computed tomographic score, IV alteplase rate and time last seen normal to presentation. There was no difference in mRS of 0 to 1 between EVT and medical management (55.7% versus 54.4%, respectively; adjusted odds ratio, 1.3; 95% CI, 0.64-2.64; P=0.47). Similar results were seen for mRS of 0 to 2 (63.3% EVT versus 67.8% medical management; adjusted odds ratio, 0.9; 95% CI, 0.43-1.88; P=0.77). In a propensity matching analysis, there was no treatment effect in 62 matched pairs (53.5% EVT, 48.4% medical management; odds ratio, 1.17; 95% CI, 0.54-2.52; P=0.69). There was no statistically significant difference when stratified by any thrombus location; M1 approached significance (P=0.07). Symptomatic intracerebral hemorrhage rates were higher with thrombectomy (5.8% EVT versus 0% medical management; P=0.02). Conclusions-Our retrospective multicenter cohort study showed no improvement in excellent and independent functional outcomes in mild strokes (NIHSS, <6) receiving thrombectomy irrespective of thrombus location, with increased symptomatic intracerebral hemorrhage rates, consistent with the guidelines recommending the treatment for NIHSS ≥6.
ndovascular thrombectomy (EVT) improved reperfusion rates and clinical outcomes over best medical management, including IV alteplase, in multiple randomized control trials (RCTs) for selected stroke patients with large vessel occlusion (LVO). [1] [2] [3] [4] [5] [6] [7] [8] [9] Based on these trials, current guidelines endorse EVT as the standard of care for patients with LVO in the anterior circulation (internal carotid artery [ICA] and middle cerebral artery/M1) with a National Institutes of Health Stroke Scale (NIHSS) score of ≥6. 10 This NIHSS cutoff was established because the previous RCTs' eligibility criteria mostly excluded patients with NIHSS <6. One exception was MR CLEAN (Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute Ischemic Stroke in the Netherlands), which enrolled patients with NIHSS as low as 2.
1 Consequently, only a restricted group of patients with mild strokes and LVO were included in those RCTs as illustrated in the HERMES (Highly Effective Reperfusion Evaluated in Multiple Endovascular Stroke Trials) pooled meta-analysis, which had limited number of patients with NIHSS <10 and even fewer had NIHSS <6. 11 Thus, there is a lack of evidence of EVT effectiveness and safety in this important subpopulation.
Many patients with LVO presenting with NIHSS <6, however, can end up with significant disability. In the absence of data, physicians face uncertainty how to manage these patients because relatively milder deficits may not seem to justify the risks of EVT. To help fill this gap in information, we explored the effectiveness and safety of EVT in LVO patients with mild strokes (NIHSS, <6) in a large, multicenter dataset that reflects worldwide daily practice.
Materials and Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Study Design, Settings, and Participants
We retrospectively pooled a cohort of patients with acute ischemic stroke from 8 US and Spain centers with anterior circulation LVO and NIHSS <6 presenting within 24 hours from last seen normal between January 2012 and March 2017. LVO was defined as an occlusion of the anterior circulation (ICA, middle cerebral artery: M1, M2, M3, M4, and anterior cerebral artery [ACA]) identified on the coronal computed tomographic (CT) angiogram, anterior-posterior projection of the magnetic resonance angiogram, or anteriorposterior conventional angiogram as read and adjudicated locally by the participating center. The study was approved by the institutional review boards of the participating centers (University of Texas, Houston, TX; Valley Baptist Hospital, Harlingen, TX; Kaiser Permanente, Los Angeles, CA; University of Tennessee, Memphis, TN; Kansas University, Kansas City, MO; Baylor College of Medicine, Dallas, TX; Rush University, Chicago, IL; and University Hospital Vall d'Hebron, Barcelona, Spain), which determined that informed consent was not required for this retrospective analysis.
Study Treatments, Exposures, and Intervention
Patients were divided into EVT and medical management groups based on their locally determined treatment. Endovascular treatment included mechanical thrombectomy by means of retrievable stents, with or without adjunctive aspiration techniques. Primary aspiration or intra-arterial thrombolytics was given in some cases. Medical management was based on current American Heart Association guidelines, including IV alteplase in patients presenting within the first 4.5 hours from last seen normal and meeting other guideline criteria. In patients not eligible for IV alteplase, an antiplatelet agent was administered on day 1, unless there was an indication for early anticoagulation.
Demographics, Variables, and Measurements
Information on baseline demographics, vascular risk factors, last seen normal, admission blood glucose level, NIHSS score (range, 0-42, with higher scores indicating severe stroke), IV alteplase administration and time, if applicable, and EVT center arrival time were obtained from the prospectively collected stroke registries of the different centers. Other clinical endpoints obtained included symptomatic intracerebral hemorrhage (sICH; defined as a parenchymal hematoma grade 2 associated with worsening neurological status thought to be related to the hematoma), neurological deterioration (defined as a ≥4-point increase in the NIHSS score), and functional outcome at 90 days as measured by modified Rankin Scale score (range, 0-6, with lower scores indicating better outcomes). Type of mechanical thrombectomy device, intra-arterial thrombolytic, conscious sedation, or general anesthesia, groin puncture time, time to recanalization (modified Thrombolysis in Ischemic Stroke score, ≥2b if achieved or end of procedure), and duration of the procedure were also reported from the respective centers' databases.
Imaging Analysis
Early ischemic changes were measured by the Alberta Stroke Program Early CT Score (ASPECTS) 12 on noncontrast-enhanced CT head scans. For recanalization, the modified Thrombolysis in Ischemic Stroke score (range, 0 [no perfusion] to 3 [full perfusion with filling of all distal branches]) 13 was used; successful reperfusion (partial and complete) was defined as a modified score ≥2b at the end of the procedure. The CT and angiographic images were adjudicated locally at the treatment center.
Study Outcomes
Ninety-day excellent outcome (mRS, 0-1) was chosen as the primary outcome because it is a more appropriate goal for mild strokes than mRS of 0 to 2. Independent outcome (mRS, 0-2) was a secondary outcome. Rates of hemorrhage and symptomatic hemorrhage (SITS-MOST criteria [Safe Implementation of Thrombolysis in StrokeMonitoring Study] 14 ) were safety outcomes. Other outcomes included rates of asymptomatic hemorrhage (parenchymal hematoma type 1 and 2) and reperfusion in the EVT group measured by the modified Thrombolysis in Ischemic Stroke score. 13 
Statistical Analysis
Demographics, baseline characteristics, and clinical outcomes in patients with EVT were compared with those who had medical management by 2-sample t test or Wilcoxon rank-sum test as appropriate for continuous variables and χ 2 test or Fisher exact test as appropriate for categorical variables. Multivariable logistic regression was conducted to evaluate the differences in outcome between the 2 groups after adjustment for prespecified variables, including age, presentation NIHSS, time last seen normal to EVT center arrival, center, IV alteplase, ASPECTS, and thrombus location. We also explored whether there was any interaction between treatment differences and treatment time windows (0-6 hours and >6-24 hours) from last seen normal to treatment time. Unadjusted odds ratio (OR) and adjusted OR (aOR) along with their 95% CIs were reported.
We assessed the interaction between thrombectomy treatment effect and thrombus location. Further exploratory analysis was done to evaluate thrombus location-specific differences in outcomes between the 2 treatment groups (EVT versus medical management) and thrombus location (M1, ICA, M2, and M3/M4/ACA), as well as dichotomized thrombus location (proximal, M1+ICA, versus distal, M2+M3+M4+ACA).
Furthermore, we matched EVT and medical management patients using propensity scores. A multivariable logistic regression model was built to calculate propensity score for each patient. The model included the following prespecified variables: age, NIHSS, IV
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October 2018 alteplase, transfer status, wake-up stroke status, onset to arrival time, and thrombus location. We applied digit-based greedy approach 15 to match patients. Initially, we matched patients with EVT to medical management patients within all thrombus locations. In addition, we matched EVT and medical management patients within each dichotomized thrombus locations (proximal and distal). We assessed the distribution of patient characteristics between 2 groups in the matched samples through 2-sample t test or Wilcoxon rank-sum test as appropriate for continuous variables and χ 2 test or Fisher exact test for categorical variables. The OR along with its 95% CI based on conditional logistic regression was reported for the matched samples. All analyses were performed using SAS 9.4 (Cary, NC), and a 2-sided P value <0.05 was considered as statistically significant.
Results

Baseline Characteristics
Two hundred fourteen patients were included; 124 received EVT and 90 medical management. The 2 groups had similar baseline age, ASPECTS, %IV alteplase, and median time (minutes, interquartile range) to EVT center as illustrated in Table 1 . Medical management patients had milder strokes (median NIHSS, 3 versus 4; P=0.005) than EVT. Most patients had middle cerebral artery occlusion (M1 or M2; EVT, 54.8% M1 and 26.6% M2) as compared with medical management (23.3% M1 and 48.9% M2), whereas 16.9% of EVT and 13.3% of medical management patients had ICA occlusions (Table 1) . Table 2 summarizes the ORs and aORs through multivariable regression analyses in the whole cohort and after stratification by thrombus location for excellent outcomes. There was no difference in excellent (mRS, 0-1) outcome between the groups (55.7% EVT versus 54.4% medical management; Figure 1A ), aOR 1.30 (95% CI, 0.64-2.64; P=0.47; Table 2 ). Similar results were seen for independent outcome (63.3% EVT versus 67.8% medical management; aOR, 0.90; 95% CI, 0.43-1.88; P=0.77; Table I in the online-only Data Supplement). There was no interaction between outcome differences with EVT versus medical management and time from last seen normal to treatment time; early (0-6 hours) versus late (>6-24 hours) time windows (P=0.98).
Clinical Outcome Comparison
Clinical Outcome Comparison by Thrombus Location
Patients with mild strokes because of proximal occlusions (M1 and ICA) were more likely to receive thrombectomy (54.8% and 16.9% EVT versus 23.3% and 13.3% medical management, respectively; P<0.001), whereas those with more distal occlusions (M2 and M3/M4) were more likely to receive medical management only (26.6% and 1.6% EVT versus 48.9% and 14.4% medical management).
There was no statistically significant interaction between thrombectomy treatment effect and thrombus location (P=0.15). Because patients with more proximal occlusions are more likely to have larger areas at risk, despite of mild deficits, we further explored whether there was a potential treatment effect difference by the different thrombus location strata. The rates of excellent outcomes were higher with EVT in patients with M1 occlusions (52.8% EVT versus 23.8% medical management; Figure 1B ) and ICA (53.8% EVT versus 41.7% medical management; Figure 1C ). For M1 occlusions, the aOR for excellent outcome was 3.31 (95% CI, 0.92-11.94; P=0.07; Table 2 ). The difference approached but did not reach statistical significance for M1 occlusions, suggesting that patients with M1 occlusions might potentially benefit from thrombectomy. There was no statistical significance for ICA occlusions (aOR, 1.95; 95% CI, 0.35-10.77; P=0.44; Table 2 ).
Conversely, it appeared that patients with more distal occlusions did not benefit with thrombectomy; M2 (64.3% EVT versus 72.7% medical management; Figure 1D ) and M3/M4/ACA (0% EVT versus 53.8% medical management; Figure I in the online-only Data Supplement). Similar results were observed for the secondary outcome (mRS, 0-2; Table  I in the online-only Data Supplement). When dichotomizing thrombus location into proximal (M1+ICA) and distal (M2+M3+M4+ACA), patients with proximal occlusions had more excellent outcomes with EVT that approached but did not reach statistical significance (53.1% EVT versus 30.3% medical management; aOR, 2.68; 95% CI, 0.98-7.32; P=0.05; Figure 2A ; Table 2 ). There was no difference in excellent outcome rates in patients with distal occlusions (60% EVT versus 68.4% medical management; Figure 2B ).
Clinical Outcome Comparison With Propensity Score Matching
We matched 62 pairs of EVT and medical management patients. The distributions of patient characteristics between 2 groups in the matched sample were similar (Table II in the online-only Data Supplement). There was no treatment effect for excellent outcome in the matched sample (53.5% EVT, 48.4% medical management; OR, 1.17; 95% CI, 0.54-2.52; P=0.69). Similar results were seen when matching within proximal and distal thrombus locations, respectively (Tables  III and IV in 
Safety Outcomes
There was no difference in the incidence of parenchymal hematoma 1 and parenchymal hematoma 2 (5.3% EVT versus 10% medical management; P=0.20; Table 3 ). However, 5.8% of patients in the EVT group had sICH, as compared with none in the medical management group (P=0.02). Further analysis of patients who had sICH did not show any difference in IV alteplase rate, ASPECTS, age, reperfusion times, NIHSS, history of hypertension, or thrombus location as compared with those who did not have sICH (Table 4) . We observed increased sICH with multiple passes during EVT (as compared with a single pass), but this difference did not reach significance (P=0.26).
There was a statistically significant association between sICH and mortality (P=0.01), and patients undergoing EVT had higher mortality (8.9% EVT versus 1.1% medical management; P=0.03).
Discussion
Patients with milder strokes usually have independent outcome but those with LVOs may face a different fate. In our cohort of patients with baseline NIHSS <6, one-third (32.2%) of those receiving medical management had 90-day mRS >2. The benefit of EVT for LVO in patients with milder stroke remains uncertain. A patient-level pooled meta-analysis of 5 RCTs showed no clear benefit of EVT in 177 patients across the entire NIHSS range of 0 to 10 (aOR, 1.67; 95% CI, 0.80-3.50; P=0.45), 11 but results in the cohort of patients with NIHSS <6 were not reported. These results are affected by the small number of patients pooled because most of these RCTs' inclusion criteria started at NIHSS threshold of 6 [2] [3] [4] [5] and MR CLEAN at 2.
1 This illustrates the need for data specifically in this subgroup of patients with mild strokes. 
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Prior studies have attempted to address outcomes with EVT in patients with milder stroke but were limited by singlecenter reporting, 16 small sample size, [16] [17] [18] or lack of a concurrent medical management group. 19 In a single-center retrospective study, Haussen et al 16 reported a shift toward better discharge NIHSS in patients with EVT (−2.5 versus 0; P<0.01), but there was no statistical difference in 90-day mRS of 0 to 2 (100% EVT versus 77% medical management; P=0. 15) or mRS of 0 to 1 (70% versus 57%, respectively; P=0. 19 ). An analysis of the GESTOR (Grady Endovascular Stroke Outcomes Registry) and STOPstroke (Screening Technology and Outcomes Project in Stroke) databases with 26 matched pairs showed increased rates of independence with EVT at 90 days (93% versus 69%; P=0.04). 18 In a 3-center single-arm study of 138 patients with NIHSS ≤7, Dargazanli et al 19, 20 reported excellent outcomes with EVT in 65% and independent outcomes in 78%, but there was no superiority of EVT when compared with medical management when the authors further evaluated data from the endovascular treatment in ischemic stroke cohort. Similarly, an analysis of 78 patients with mild LVO stroke (NIHSS, ≤5) from the multicenter SONIIA registry (Sistema Online d'Informació de l'Ictus Agut) 17 showed no benefit of EVT over medical treatment (58.8% EVT versus 68.2% medical management; P=0.39) with an excess of sICH in patients receiving EVT (11.8%). IV thrombolysis was the single independent predictor of independent outcome in that cohort. With 3 studies reporting no adjunctive benefit with EVT in this population and 1 reporting increased rates of independent outcomes, these inconclusive results emphasize the need for additional higher quality data in this population.
Our results showed there was no overall EVT treatment benefit in patients with NIHSS <6. In a secondary analysis comparing the 2 treatments stratified by thrombus location, patients with more proximal occlusions (ICA and M1) were more likely to receive EVT compared with those with more distal occlusions. Because patients with more proximal occlusions would, theoretically, have a larger area at risk, it is plausible that there would be an interaction between thrombectomy treatment effect and thrombus location. Our data did not support treatment effect modification by the overall thrombus location. We, however, conducted further exploratory analyses to look at treatment effect difference after stratifying by thrombus location. Although not statistically significant, and limited by small numbers, our analyses suggested that patients with more distal occlusions have better outcome with medical management. Furthermore, our data showed that there might be a potential treatment effect for patients with M1 occlusions as the difference approached statistical significance. These analyses need to be verified in other cohorts, hopefully with randomized data. If thrombectomy is to be studied further in LVO patients with NIHSS <6, our data suggest that only patients with proximal occlusions should be the target population. Furthermore, we performed propensity matching as a sensitivity and confirmatory analysis, and the results remained the same with no statistical significance in outcome differences between EVT and medical management groups.
In regard to safety outcomes, although the rate of disability was the same in both groups, EVT was associated with higher rates of sICH and mortality compared with medical management. These findings support the concerns around the safety of the intervention in this population and advocate for a careful approach when entertaining mild strokes with LVO for thrombectomy.
Our findings are limited by the retrospective design and lack of a randomized comparison group. Although a randomized trial would provide the highest level of evidence, it may have significant feasibility challenges. RCT in this population would be difficult to power because there was no treatment 
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effect when including all thrombus locations, difficult to enroll given the limited number of patients would meet the eligibility criteria if the trial was restricted to only proximal occlusions and difficult to execute given the difficulty differentiating patients with 1 or 2 points differences in NIHSS (<6 versus ≥6). The lack of randomized data in this population is probably because of the fact that this is a challenging population to conduct an RCT on. Having said that, there are 2 RCTs that are currently being planned. These trials will bring conclusive answers and complement our data. In the meanwhile, however, our data serve as a good level of foundational evidence. The other limitation of our study is that although the EVT and medical management groups were mostly similar in baseline characteristics, the patients were from 8 centers with different EVT criteria where selection for thrombectomy was not randomized and was based on institutional protocols and treating physicians' decisions. Selection bias might have occurred because those patients who were viewed as more likely to benefit from EVT were the ones treated with the intervention. Furthermore, there were differences in baseline characteristics, and given the nature of the retrospective study, treatment decision was not randomized or prospectively protocolized. We attempted to account for these treatment patterns by utilizing multivariable regression models for adjustment and performing propensity matching analyses, but this might not have completely accounted for selection biases because patients who were felt to benefit from thrombectomy by the treating physicians were undoubtedly selected for the treatment. Although we adjusted for variables known to affect clinical outcomes, the lack of randomization prevented us from accounting for unmeasured covariates. We only have data on CT changes (ASPECTS) as a baseline imaging modality and we considered that in our analyses. Other advanced imaging modalities, which further evaluate at risk tissue, such as CT perfusion, magnetic resonance perfusion, and collateral status might have been taken into consideration to guide treatment decisions. The strength of our data is that it represents a large cohort derived from real-world daily practice with a concurrent medical management group.
Conclusions
Our retrospective multicenter cohort study showed no increase in excellent and independent functional outcomes in patients receiving EVT, with increased rates of sICH and mortality rates. These findings are consistent with the current guidelines that recommend the treatment only in patients with NIHSS ≥6. 
